Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM grew its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 92.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 392,262 shares of the biopharmaceutical company's stock after purchasing an additional 188,836 shares during the quarter. Monaco Asset Management SAM owned approximately 0.67% of Vanda Pharmaceuticals worth $1,879,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company's stock worth $6,689,000 after buying an additional 94,870 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 4.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after buying an additional 38,449 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Vanda Pharmaceuticals by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company's stock worth $2,796,000 after buying an additional 3,473 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company's stock worth $1,071,000 after buying an additional 11,524 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $864,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Vanda Pharmaceuticals Stock Down 1.8 %

Shares of Vanda Pharmaceuticals stock traded down $0.09 during trading hours on Tuesday, hitting $4.99. 454,055 shares of the company's stock traded hands, compared to its average volume of 1,136,605. The stock has a 50 day simple moving average of $4.61 and a 200-day simple moving average of $4.76. The company has a market cap of $291.00 million, a PE ratio of -15.59 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a twelve month low of $3.71 and a twelve month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Activity

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Tuesday, February 25th. The shares were acquired at an average price of $4.46 per share, with a total value of $44,600.00. Following the completion of the transaction, the chief executive officer now owns 2,331,730 shares of the company's stock, valued at approximately $10,399,515.80. This trade represents a 0.43 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired 32,000 shares of company stock worth $151,180 over the last ninety days. Corporate insiders own 8.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VNDA shares. HC Wainwright increased their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.